Literature DB >> 31206731

A hypothesis testing procedure for random changepoint mixed models.

Corentin Segalas1, Hélène Amieva1, Hélène Jacqmin-Gadda1.   

Abstract

In biomedical research, random changepoint mixed models are used to take into account an individual breakpoint in a biomarker trajectory. This may be observed in the cognitive decline measured by psychometric tests in the prediagnosis phase of Alzheimer's disease. The existence, intensity and duration of this accelerated decline can depend on individual characteristics. The main objective of our work is to propose inferential methods to assess the existence of this phase of accelerated decline, ie, the existence of a random changepoint. To do so, we use a mixed model with two linear phases and test the nullity of the parameter measuring the difference of slopes between the two phases. Because we face the issue of nuisance parameters being unidentifiable under the null hypothesis, the supremum of the classic score test statistic on these parameters is used. The asymptotic distribution of the supremum under the null is approached with a perturbation method based on the multiplier bootstrap. The performance of our testing procedure is assessed via simulations and the test is applied to the French cohort PAQUID of elderly subjects to study the shape of the prediagnosis decline according to educational level. The test is significant for both educational levels and the estimated trajectories confirmed that educational level is a good marker for cognitive reserve.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Alzheimer; cognitive reserve; nonidentifiability; random changepoint; score test

Mesh:

Substances:

Year:  2019        PMID: 31206731     DOI: 10.1002/sim.8195

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  Power analysis of longitudinal studies with piecewise linear growth and attrition.

Authors:  Mirjam Moerbeek
Journal:  Behav Res Methods       Date:  2022-02-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.